Aducanumab has its approval — now, let citizen-scientists come together to see if it works
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today.
Editor’s Note: Madhav Thambisetty was an advisor on the FDA’s Peripheral and Central Nervous System Drugs advisory committee that voted overwhelmingly not to recommend …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
